March 2024 - Page 5 of 11

The Complex Impact of CMV Reactivation Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comprehensive Review

By Qingyuan Liu 2024.03.17

Abstract: Cytomegalovirus (CMV) reactivation presents a formidable challenge for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with implications for overall mortality (OM) and non-relapse mortality (NRM) that are subject…

Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Option for Diffuse Large B-Cell Lymphoma Patients After CAR-T Therapy Failure

By Yang Xiaoshan 2024.03.17

Abstract: Refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) poses significant therapeutic challenges, particularly in cases where chimeric antigen receptor T-cell (CAR-T) therapy fails. This retrospective study aimed to evaluate the…

Exploring CD22 as an Alternative Target in B-cell Hematologic Malignancies: A Comprehensive Review of Study Design, Clinical Implications, and Future Perspectives

By Mourabit Halima 2024.03.17

Abstract: Chimeric antigen receptor (CAR)-T cell therapy targeting CD19 has revolutionized the treatment landscape for patients with relapsed or refractory (R/R) B-cell malignancies. However, the emergence of relapse with CD19-negative…

$Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results$

Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

By Mourabit Halima 2024.03.17

Abstract: Multiple myeloma (MM) poses significant therapeutic challenges due to its heterogeneous nature. Bispecific chimeric antigen receptor T (CAR-T) cell therapy targeting CS1 and BCMA antigens offers a novel approach.…

Evaluating the Efficacy and Safety of Orelabrutinib-Based Regimens in Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

By Mourabit Halima 2024.03.17

Abstract: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous malignancy associated with significant morbidity and mortality. Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown promise as a therapeutic agent…

Retrospective Analysis of bZIP Region Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia: Implications for Prognosis and Treatment

By Mourabit Halima 2024.03.17

Editor's note: Acute Myeloid Leukemia (AML) characterized by CCAAT-enhancer binding protein alpha (CEBPA) double mutations (CEBPAdm) represents a distinct subtype with varying clinical outcomes. Recent attention has focused on the…

The Impact of CEBPA Mutations in Hematological Disorders: A Comprehensive Study

By Mourabit Halima 2024.03.17

Editor's note: Genetic mutations play a pivotal role in shaping the clinical presentation and prognosis of hematological disorders, with CEBPA mutations emerging as significant contributors to disease pathogenesis. This comprehensive…

Pediatric-Inspired Therapy Revolutionizes Treatment of Adult Acute Lymphoblastic Leukemia: Insights from a Groundbreaking Chinese Study

By Mourabit Halima 2024.03.15

Introduction: Acute lymphoblastic leukemia (ALL) poses significant challenges in adult patient care, necessitating innovative treatment strategies. Addressing this need, a pioneering study conducted in China investigated the efficacy and safety…

the Role of the Pinch-Cxcl12-Mbl2 Pathway in Immune and Hematopoietic Homeostasis: Implications for Therapeutic Interventions

By Mourabit Halima 2024.03.15

Editor's note: The interplay between bone marrow stromal cells (BMSCs) and immune as well as hematopoietic functions is a complex yet crucial aspect of maintaining overall health. In this study,…

Intensified Conditioning Regimens for High-Risk ALL Patients Undergoing Allo-HSCT: A Retrospective Analysis

By Mourabit Halima 2024.03.15

Editor's note: The prognosis of high-risk acute lymphoblastic leukemia (ALL) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains variable, particularly concerning minimal residual disease (MRD) status. Professor Yu Hu…